Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

NUVB vs RVMD

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NUVB
Nuvation Bio Inc.

Biotechnology

HealthcareNYSE • US
Market Cap$1.75B
5Y Perf.-49.6%
RVMD
Revolution Medicines, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$32.12B
5Y Perf.+433.1%

NUVB vs RVMD — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NUVB logoNUVB
RVMD logoRVMD
IndustryBiotechnologyBiotechnology
Market Cap$1.75B$32.12B
Revenue (TTM)$143M$0.00
Net Income (TTM)$-146M$-1.37B
Gross Margin91.6%
Operating Margin-105.0%
Total Debt$10M$159M
Cash & Equiv.$164M$384M

NUVB vs RVMDLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NUVB
RVMD
StockAug 20May 26Return
Nuvation Bio Inc. (NUVB)10050.4-49.6%
Revolution Medicine… (RVMD)100533.1+433.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: NUVB vs RVMD

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: RVMD leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Nuvation Bio Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
NUVB
Nuvation Bio Inc.
The Growth Play

NUVB is the clearest fit if your priority is growth exposure.

  • Rev growth 7.0%, EPS growth 71.6%
  • 7.0% revenue growth vs RVMD's -98.6%
  • -23.8% ROA vs RVMD's -59.1%, ROIC -54.3% vs -54.3%
Best for: growth exposure
RVMD
Revolution Medicines, Inc.
The Income Pick

RVMD carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • beta 1.08
  • 422.7% 10Y total return vs NUVB's -49.6%
  • Lower volatility, beta 1.08, Low D/E 9.7%, current ratio 7.14x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthNUVB logoNUVB7.0% revenue growth vs RVMD's -98.6%
Quality / MarginsRVMD logoRVMD2.8% margin vs NUVB's -102.1%
Stability / SafetyRVMD logoRVMDBeta 1.08 vs NUVB's 2.04
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)RVMD logoRVMD+303.5% vs NUVB's +141.1%
Efficiency (ROA)NUVB logoNUVB-23.8% ROA vs RVMD's -59.1%, ROIC -54.3% vs -54.3%

NUVB vs RVMD — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

NUVBNuvation Bio Inc.
FY 2025
License
60.8%$38M
Product
39.2%$25M
RVMDRevolution Medicines, Inc.
FY 2022
Collaboration Revenue Member
100.0%$35M

NUVB vs RVMD — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLNUVBLAGGINGRVMD

Income & Cash Flow (Last 12 Months)

NUVB leads this category, winning 1 of 1 comparable metric.

NUVB and RVMD operate at a comparable scale, with $143M and $0 in trailing revenue.

MetricNUVB logoNUVBNuvation Bio Inc.RVMD logoRVMDRevolution Medici…
RevenueTrailing 12 months$143M$0
EBITDAEarnings before interest/tax-$145M-$1.4B
Net IncomeAfter-tax profit-$146M-$1.4B
Free Cash FlowCash after capex-$126M-$1.1B
Gross MarginGross profit ÷ Revenue+91.6%
Operating MarginEBIT ÷ Revenue-105.0%
Net MarginNet income ÷ Revenue-102.1%
FCF MarginFCF ÷ Revenue-88.1%
Rev. Growth (YoY)Latest quarter vs prior year+26.0%
EPS Growth (YoY)Latest quarter vs prior year+106.3%-102.7%
NUVB leads this category, winning 1 of 1 comparable metric.

Valuation Metrics

Evenly matched — NUVB and RVMD each lead in 1 of 2 comparable metrics.
MetricNUVB logoNUVBNuvation Bio Inc.RVMD logoRVMDRevolution Medici…
Market CapShares × price$1.7B$32.1B
Enterprise ValueMkt cap + debt − cash$1.6B$31.9B
Trailing P/EPrice ÷ TTM EPS-8.40x-25.39x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue27.82x
Price / BookPrice ÷ Book value/share5.63x17.61x
Price / FCFMarket cap ÷ FCF
Evenly matched — NUVB and RVMD each lead in 1 of 2 comparable metrics.

Profitability & Efficiency

NUVB leads this category, winning 7 of 9 comparable metrics.

NUVB delivers a -44.1% return on equity — every $100 of shareholder capital generates $-44 in annual profit, vs $-83 for RVMD. NUVB carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to RVMD's 0.10x. On the Piotroski fundamental quality scale (0–9), NUVB scores 4/9 vs RVMD's 1/9, reflecting mixed financial health.

MetricNUVB logoNUVBNuvation Bio Inc.RVMD logoRVMDRevolution Medici…
ROE (TTM)Return on equity-44.1%-83.2%
ROA (TTM)Return on assets-23.8%-59.1%
ROICReturn on invested capital-54.3%-54.3%
ROCEReturn on capital employed-42.8%-53.0%
Piotroski ScoreFundamental quality 0–941
Debt / EquityFinancial leverage0.03x0.10x
Net DebtTotal debt minus cash-$154M-$225M
Cash & Equiv.Liquid assets$164M$384M
Total DebtShort + long-term debt$10M$159M
Interest CoverageEBIT ÷ Interest expense-162.11x-81.62x
NUVB leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

RVMD leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in RVMD five years ago would be worth $52,093 today (with dividends reinvested), compared to $4,574 for NUVB. Over the past 12 months, RVMD leads with a +303.5% total return vs NUVB's +141.1%. The 3-year compound annual growth rate (CAGR) favors RVMD at 83.5% vs NUVB's 46.0% — a key indicator of consistent wealth creation.

MetricNUVB logoNUVBNuvation Bio Inc.RVMD logoRVMDRevolution Medici…
YTD ReturnYear-to-date-41.3%+91.2%
1-Year ReturnPast 12 months+141.1%+303.5%
3-Year ReturnCumulative with dividends+211.1%+518.1%
5-Year ReturnCumulative with dividends-54.3%+420.9%
10-Year ReturnCumulative with dividends-49.6%+422.7%
CAGR (3Y)Annualised 3-year return+46.0%+83.5%
RVMD leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

RVMD leads this category, winning 2 of 2 comparable metrics.

RVMD is the less volatile stock with a 1.08 beta — it tends to amplify market swings less than NUVB's 2.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RVMD currently trades 97.0% from its 52-week high vs NUVB's 51.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNUVB logoNUVBNuvation Bio Inc.RVMD logoRVMDRevolution Medici…
Beta (5Y)Sensitivity to S&P 5002.04x1.08x
52-Week HighHighest price in past year$9.75$155.70
52-Week LowLowest price in past year$1.57$34.00
% of 52W HighCurrent price vs 52-week peak+51.7%+97.0%
RSI (14)Momentum oscillator 0–10054.064.2
Avg Volume (50D)Average daily shares traded4.3M3.0M
RVMD leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates NUVB as "Buy" and RVMD as "Buy". Consensus price targets imply 146.0% upside for NUVB (target: $12) vs 2.5% for RVMD (target: $155).

MetricNUVB logoNUVBNuvation Bio Inc.RVMD logoRVMDRevolution Medici…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$12.40$154.80
# AnalystsCovering analysts922
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

NUVB leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RVMD leads in 2 (Total Returns, Risk & Volatility). 1 tied.

Best OverallNuvation Bio Inc. (NUVB)Leads 2 of 6 categories
Loading custom metrics...

NUVB vs RVMD: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is NUVB or RVMD a better buy right now?

Analysts rate Nuvation Bio Inc.

(NUVB) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — NUVB or RVMD?

Over the past 5 years, Revolution Medicines, Inc.

(RVMD) delivered a total return of +420. 9%, compared to -54. 3% for Nuvation Bio Inc. (NUVB). Over 10 years, the gap is even starker: RVMD returned +422. 7% versus NUVB's -49. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — NUVB or RVMD?

By beta (market sensitivity over 5 years), Revolution Medicines, Inc.

(RVMD) is the lower-risk stock at 1. 08β versus Nuvation Bio Inc. 's 2. 04β — meaning NUVB is approximately 88% more volatile than RVMD relative to the S&P 500. On balance sheet safety, Nuvation Bio Inc. (NUVB) carries a lower debt/equity ratio of 3% versus 10% for Revolution Medicines, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — NUVB or RVMD?

On earnings-per-share growth, the picture is similar: Nuvation Bio Inc.

grew EPS 71. 6% year-over-year, compared to -66. 2% for Revolution Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — NUVB or RVMD?

Revolution Medicines, Inc.

(RVMD) is the more profitable company, earning 0. 0% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RVMD leads at 0. 0% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — NUVB leads at 86. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — NUVB or RVMD?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is NUVB or RVMD better for a retirement portfolio?

For long-horizon retirement investors, Revolution Medicines, Inc.

(RVMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 08), +422. 7% 10Y return). Nuvation Bio Inc. (NUVB) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RVMD: +422. 7%, NUVB: -49. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between NUVB and RVMD?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NUVB is a small-cap high-growth stock; RVMD is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

NUVB

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 1299%
  • Gross Margin > 54%
Run This Screen
Stocks Like

RVMD

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.